Feature | December 23, 2013

PCI Performance Measures Include Patient Selection, Appropriateness

Measures examine care before, during, after procedure

December 23, 2013 — Careful documentation of patient selection and procedure appropriateness are critical — yet underutilized — steps in ensuring high-quality clinical care for percutaneous coronary intervention (PCI), according to performance measures released by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society for Cardiovascular Angiography and Interventions (SCAI), the AMA-Convened Physician Consortium for Performance Improvement and the National Committee for Quality Assurance (NCQA).
 
Designed to benchmark and improve the quality of PCI, the set of performance measures includes 11 measures that address both ambulatory and inpatient settings, with two measures that address documentation and appropriateness. The document focuses primarily on elective PCI.
 
The new set of measures breaks important ground for performance measurement examining care before, during and after the procedure. It is the first set of cardiovascular performance measures to directly address procedure appropriateness. In addition, the measures incorporate other indicators of quality such as procedural volume and whether the institution benchmarks care by participating in regional or national registries.
 
The 11 measures are:
  1. Comprehensive documentation of the reasons for PCI
  2. An appropriate reason for elective PCI  (benefits outweigh the risks)  
  3. An evaluation of the individual’s ability to receive dual antiplatelet therapy (conducted before the procedure)
  4. The use of embolic protection devices in the treatment of saphenous vein bypass graft disease
  5. An assessment of renal function before the procedure (including glomerular filtration rate) and the documentation of contrast used during the procedure
  6. Documentation of the radiation dose used during the procedure
  7. The prescription of optimal medical therapy at discharge (aspirin, PY12 inhibitors and statins)   
  8. A referral to an outpatient cardiac rehabilitation program (to reduce the risk of recurrent events)   
  9. Participation in a regional or national PCI registry  
  10. The average annual volume of PCIs performed by the physician over the last two calendars years
  11. The average annual volume of PCIs performed by the hospital over the last calendar year
 
Measures 1, 3, 5, 7, 8, 9 and 11 are performance measures, while 2, 4, 6, and 10 are quality metrics. Quality metrics may not meet all specifications of formal performance measures or may be associated with unintended consequences of public reporting.
 
According to the writing committee, the measures may “serve as vehicles to accelerate appropriate translation of scientific evidence into clinical practice.” The committee goal was to create measures that capture many important aspects of quality while minimizing the reporting burden.
 
“Hospitals and health systems are increasingly facing a burden with measurement across multiple conditions and services,” said Carl Tommaso, M.D., interventional cardiologist, NorthShore University HealthSystem, and writing committee co-chair. “We wanted to focus on those aspects of PCI care that we thought would give us the greatest yield in terms of improving patient care.”
 
Brahmajee Nallamothu, M.D., associate professor of cardiovascular medicine, Department of Internal Medicine, University of Michigan, and writing committee co-chair, said this document is the first step in the evolving process of performance measurement.  
 
“Through these measures, we have moved beyond simple measurement of a few treatments to incorporating key concepts like appropriateness,” said Nallamothu. “There is still much more work to be done, however, and an important part of this process was to identify important areas for future investigation.”
 
The committee identified four areas of research that will generate better performance measures in the future:
  1. Measuring the filling of prescriptions (not just the prescription of drugs) and optimal dosing
  2. Better utilizing current data systems to track PCI quality
  3. Building accountability by all practitioners involved into quality metrics
  4. Utilizing patient surveys to track performance
 
The 2013 Performance Measures for Adults Undergoing Percutaneous Coronary Intervention is available on the ACC website and AHA websites and in future print issues of Journal of the American College of Cardiology (JACC) and Circulation: Journal of the American Heart Association.
 
For more information: www.cardiosource.org, www.americanheart.org

Related Content

Technology | Radiation Dose Management| January 19, 2017
Zetta Medical Technologies announced the release of Zia, an iterative reconstruction solution that enables the use of...
diagnostic low-dose radiation exposure, radiological imaging dose, radiophobia, Journal of Nuclear Medicine, ALARA, LNTH
News | Radiation Dose Management| January 18, 2017
In an article published in the January 2017 issue of The Journal of Nuclear Medicine, researchers assert that exposure...
electronic health records, EHR, warfarin therapy management, University of Missouri Health Care, blood thinner
News | Antiplatelet and Anticoagulation Therapies| January 17, 2017
Warfarin is a commonly prescribed blood thinner used to prevent harmful blood clots. However, the drug requires...
Lumedx, CVIS, Baylor Scott & White Health, BHVH, Texas
News | Cardiac PACS| January 17, 2017
Lumedx Corp. recently announced that it has implemented Phase 1 of a long-term, multiphase cardiovascular information...
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
Overlay Init